Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.36 |
| ▸ | DRD3 | P35462 | 8/20 | 0.36 |
| ▸ | DRD4 | P21917 | 6/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 4/20 | 0.33 |
| ▸ | DRD5 | P21918 | 4/20 | 0.33 |
| ▸ | HTR1D | P28221 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808209 | 1.00 | DRD2 (0.36) | DRD2DRD3DRD4HTR5ADRD1 | |
| SCHEMBL6809472 | 0.78 | DRD1 (0.43) | DRD1 | |
| SCHEMBL6812143 | 0.68 | CA14 (0.42) | DRD2DRD4HTR1D | |
| SCHEMBL6808310 | 0.67 | ESR1 (0.36) | DRD2DRD4HTR1D | |
| SCHEMBL5097946 | 0.66 | HTR1D (0.43) | DRD2DRD4HTR1D | |
| SCHEMBL6812077 | 0.66 | HTR1D (0.43) | DRD2DRD4HTR1D | |
| SCHEMBL6808344 | 0.66 | HTT (0.37) | DRD2DRD4HTR1D | |
| SCHEMBL6812426 | 0.66 | HTT (0.37) | DRD2DRD4HTR1D | |
| SCHEMBL6551602 | 0.65 | DRD2 (0.34) | DRD2HTR1D | |
| SCHEMBL6551574 | 0.65 | KEAP1 (0.54) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | DRD2 1606/4885DRD3 705/4885DRD4 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.